Andrew G. Myers

Andrew Myers is the Amory Houghton Professor of Chemistry at Harvard.

Myers' research program involves the synthesis and study of complex molecules of importance in biology and human medicine. His group has developed laboratory synthetic routes to a broad array of complex natural products, including the ene-diyne antibiotics neocarzinostatin chromophore, dynemicin A, N1999A2, and kedarcidin chromophore, undertakings greatly complicated by the chemical instability of all members of the class. His laboratory developed the first practical synthetic route to the tetracycline antibiotics, allowing for the synthesis of more than three thousand fully synthetic analogs (compounds inaccessible by semi-synthesis: chemical modification of natural products) by a scalable process. A portfolio of clinical candidates for the treatment of infectious diseases, all fully synthetic tetracycline analogs, are currently in development at Tetraphase Pharmaceuticals, a company founded by Myers. 

Myers received his B.S. from MIT and his Ph.D. from Harvard. He was on the faculty at Caltech before joining the Department of Chemistry and Chemical Biology at Harvard in 1998.